All News

2016

August

Media Release / Aug 03, 2016

Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer

Read More

May

Media Release / May 25, 2016

Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event

Read More
Media Release / May 18, 2016

MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer

Read More
2015

October

Media Release / Oct 27, 2015

Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance

Read More
Media Release / Oct 21, 2015

Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma

Read More

September

Media Release / Sep 24, 2015

Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires

Read More

August

Media Release / Aug 27, 2015

Novartis International BioCamp highlights how collaboration and diversity drive innovation and inspires future science leaders

Read More

June

Media Release / Jun 18, 2015

Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day

Read More

January

Media Release / Jan 07, 2015

Novartis collaborates with Intellia Therapeutics and Caribou Biosciences to explore making medicines and drug discovery tools with CRISPR genome editing technology

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More